Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.

Hanania NA, Calverley PM, Dransfield MT, Karpel JP, Brose M, Zhu H, Goehring UM, Rowe P.

Respir Med. 2014 Feb;108(2):366-75. doi: 10.1016/j.rmed.2013.09.018. Epub 2013 Sep 30.

2.

Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.

Bateman ED, Rabe KF, Calverley PM, Goehring UM, Brose M, Bredenbröker D, Fabbri LM.

Eur Respir J. 2011 Sep;38(3):553-60. doi: 10.1183/09031936.00178710. Epub 2011 Jul 7.

3.

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ.

Respir Res. 2011 Jan 27;12:18. doi: 10.1186/1465-9921-12-18.

4.

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups..

Lancet. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. Erratum in: Lancet. 2010 Oct 2;376(9747):1146.

PMID:
19716960
5.

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.

Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF.

Int J Chron Obstruct Pulmon Dis. 2012;7:375-82. doi: 10.2147/COPD.S31100. Epub 2012 Jun 20.

6.

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF.

Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13.

PMID:
25684586
7.

Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.

Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM.

Am J Respir Crit Care Med. 2007 Jul 15;176(2):154-61. Epub 2007 Apr 26.

PMID:
17463412
8.
9.

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

Chong J, Poole P, Leung B, Black PN.

Cochrane Database Syst Rev. 2011 May 11;(5):CD002309. doi: 10.1002/14651858.CD002309.pub3. Review.

PMID:
21563134
10.

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

Chong J, Leung B, Poole P.

Cochrane Database Syst Rev. 2013 Nov 4;(11):CD002309. doi: 10.1002/14651858.CD002309.pub4. Review.

PMID:
24190161
11.

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.

Porpodis K, Domvri K, Zarogoulidis P, Petridis D, Tsirgogianni K, Papaioannou A, Hatzizisi O, Kioumis I, Liaka A, Kikidaki V, Lampaki S, Organtzis J, Zarogoulidis K.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 15;10:1123-8. doi: 10.2147/COPD.S83205. eCollection 2015.

12.

A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

Rutten-van Mölken MP, van Nooten FE, Lindemann M, Caeser M, Calverley PM.

Pharmacoeconomics. 2007;25(8):695-711.

PMID:
17640111
13.

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.

Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD.

Lancet. 2005 Aug 13-19;366(9485):563-71.

PMID:
16099292
14.

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups..

Lancet. 2009 Aug 29;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6.

PMID:
19716961
15.

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.

Samyshkin Y, Kotchie RW, Mörk AC, Briggs AH, Bateman ED.

Eur J Health Econ. 2014 Jan;15(1):69-82. doi: 10.1007/s10198-013-0456-5. Epub 2013 Feb 8.

16.

Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.

Rennard SI, Sun SX, Tourkodimitris S, Rowe P, Goehring UM, Bredenbröker D, Calverley PM.

Int J Chron Obstruct Pulmon Dis. 2014 Jun 24;9:657-73. doi: 10.2147/COPD.S55738. eCollection 2014.

17.

Efficacy of roflumilast in the COPD frequent exacerbator phenotype.

Wedzicha JA, Rabe KF, Martinez FJ, Bredenbröker D, Brose M, Goehring UM, Calverley PM.

Chest. 2013 May;143(5):1302-11. doi: 10.1378/chest.12-1489.

PMID:
23117188
18.

Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA.

Vos W, Hajian B, De Backer J, Van Holsbeke C, Vinchurkar S, Claes R, Hufkens A, Parizel PM, Bedert L, De Backer W.

Int J Chron Obstruct Pulmon Dis. 2016 Feb 4;11:263-71. doi: 10.2147/COPD.S93830. eCollection 2016.

19.

Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.

Lee SD, Hui DS, Mahayiddin AA, Roa CC Jr, Kwa KH, Goehring UM, Bredenbröker D, Kuo HP.

Respirology. 2011 Nov;16(8):1249-57. doi: 10.1111/j.1440-1843.2011.02038.x.

PMID:
21848706
20.

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.

Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M.

Int J Chron Obstruct Pulmon Dis. 2013;8:79-87. doi: 10.2147/COPD.S37486. Epub 2013 Jan 30.

Supplemental Content

Support Center